Zhang ZN, Sang LX. Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it. World J Gastroenterol 2024; 30(36): 4025-4030 [PMID: 39351254 DOI: 10.3748/wjg.v30.i36.4025]
Corresponding Author of This Article
Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, The Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 28, 2024; 30(36): 4025-4030 Published online Sep 28, 2024. doi: 10.3748/wjg.v30.i36.4025
Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it
Zi-Ning Zhang, Li-Xuan Sang
Zi-Ning Zhang, Li-Xuan Sang, Department of Gastroenterology, The Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Author contributions: Zhang ZN wrote the original draft; Sang LX revised the manuscript; all authors have read and approved the final version of the manuscript.
Supported byThe Science and Technology Plan of Liaoning Province, China, No. 2022JH2/101500063.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, The Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Received: July 21, 2024 Revised: August 24, 2024 Accepted: September 6, 2024 Published online: September 28, 2024 Processing time: 61 Days and 0.9 Hours
Abstract
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease. With the emergence of biologics and other therapeutic methods, two biologics or one biologic combined with a novel small-molecule drug has been proposed in recent years to treat IBD. Although treatment strategies for IBD are being optimized, their efficacy and risks still warrant further consideration. This editorial explores the current risks associated with dual-targeted treatment for IBD and the great potential that fecal microbiota transplantation (FMT) may have for use in combination therapy for IBD. We are focused on addressing refractory IBD or biologically resistant IBD based on currently available dual-targeted treatment by incorporating FMT as part of this dual-targeted treatment. In this new therapy regimen, FMT represents a promising combination therapy.
Core Tip: The combination of biologic agents or the combination of a biologic agent and a novel small-molecule drug for treating inflammatory bowel disease (IBD) carries certain risks, and some patients are resistant to these drugs. The regulation of the gut microbiota has become a potential treatment for IBD, and the inclusion of fecal bacteria transplantation in dual-targeted treatments for IBD holds great promise.
